AASLD /TASL - Delta Hepatitis: What is New?

Nov 09 2025
Convention Center: Room 143, Level 1
9:45 AM - 10:45 AM

World Class Speakers

Ramazan Idilman, MD, FAASLD
Presenter

Ramazan Idilman, MD, FAASLD

Ankara University School of Medicine
Gupse Adali, MD
Presenter

Gupse Adali, MD

University of Health Sciences Istanbul Umraniye Hospital
Tatyana Kushner, MD, MSCE
Presenter

Tatyana Kushner, MD, MSCE
Robert J. Wong, MD, MS, FACG, FAASLD
Presenter

Robert J. Wong, MD, MS, FACG, FAASLD

VA Palo Alto Healthcare System
Jose D Debes, MD, PhD, FAASLD
Moderator

Jose D Debes, MD, PhD, FAASLD

University of Minnesota
Zeki Karasu, MD, MD
Moderator

Zeki Karasu, MD, MD

Description

The hepatitis D virus is a defective small RNA virus that causes acute hepatitis, acute liver failure, and chronic hepatitis, often leading to rapid progression to cirrhosis and its complications. In this Community Conservation, we will review recent updates on the epidemiological data of HDV, the clinical course of HDV-related liver disease, and the challenges associated with HDV treatment.

Journey Maps

Presentations

9:45 AM - 9:47 AM
Nov 09 2025
Washington, D.C.

Welcome

Jose D Debes, MD, PhD, FAASLD, Moderator
Hepatitis
9:47 AM - 10:02 AM
Nov 09 2025
Washington, D.C.

HDV Clinical Update

Tatyana Kushner, MD, MSCE, Presenter
Hepatitis
10:02 AM - 10:17 AM
Nov 09 2025
Washington, D.C.

HDV Treatment Pipeline

Ramazan Idilman, MD, FAASLD, Presenter
Hepatitis
10:17 AM - 10:27 AM
Nov 09 2025
Washington, D.C.

Debate: Should HDV screening be mandatory for all HBsAg-positive individuals (Pro)

Gupse Adali, MD, Presenter
Hepatitis
10:27 AM - 10:37 AM
Nov 09 2025
Washington, D.C.

Debate: Should HDV screening be mandatory for all HBsAg-positive individuals (Con)

Robert J. Wong, MD, MS, FACG, FAASLD, Presenter
Hepatitis
10:37 AM - 10:45 AM
Nov 09 2025
Washington, D.C.

Q&A/Close

Zeki Karasu, MD, MD, Moderator
Hepatitis

Objectives

  • To determine the recent global prevalence of HDV
  • To recognize the latest updates on the clinical characterization and prognostic assessment of HDV-related liver disease
  • To summarize current treatment strategies and investigational therapies for HDV infection.